Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials

EP: 1.Differences Between SERDs and Other Therapies

EP: 2.Efficacy of Oral SERDs in the EMERALD Trial

EP: 3.Safety Concerns Associated With Oral SERDs

EP: 4.Benefits of Using Oral SERDs

EP: 5.Progression-Free Survival of Oral SERDs in Clinical Practice

EP: 6.Role of Oral SERDs in Treatment of ER+/HER2- in Metastatic Breast Cancer

EP: 7.ESR1 Mutation Confirmation With Oral SERDs

EP: 8.Coverage Considerations for Oral SERDs

EP: 9.Clinical Impact of Oral SERDs

EP: 10.Treatment Failure and Resistance Before Oral SERDs

EP: 11.Cardiovascular Risk and Menopausal Symptoms Associated With Oral SERDs

EP: 12.Monitoring and Managing Adverse Effects With Oral SERDs

EP: 13.Payer Perspectives on SERDs

EP: 14.Ensuring Access to Oral SERDs

EP: 15.How Patient Advocates Can Help the Newly Diagnosed

EP: 16.Empowering Patients With Metastatic Breast Cancer

Now Viewing

EP: 17.Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials

EP: 18.Guiding Patients Through Complex Treatment Decisions

EP: 19.Patient Advocate's Role in Shared Decision Making

EP: 20.Helping Patients Overcome Health Disparities as a Patient Advocate

Sonya Negley, IOM, CSMA: I think there are a few things we can do as organizations. We can make sure we are educating patients about what is available in clinical trials, and we as patient advocacy organizations need to look at it comprehensively, not just trials that may or may not be on clinicaltrials.gov, but clinical trials in general, and how can those trials support the patient? I think we have to be very cautious that it’s not the patient’s work to go out and make sure all of the trials have patients involved or that type of thing. But more so, giving their input in the way they feel they can best share their voice.

We want people who are living with metastatic breast cancer to feel like they are doing everything in their life that they want to do. Their lives are shortened, and it is incredibly important that they spend time with their loved ones. And it’s important for all of us to remember, whether we’re in research, science, or in patient advocacy, that people’s time that we’re using is time they’re taking away from their loved ones. So, [we need to] be efficient in making sure their goals are met, and [understanding] it’s a very important task, and [helping patients realize] that their participation is going to reward them personally, as well as rewarding discovery in this space.

Transcript edited for clarity.